Prominent biotech Biogen (NASDAQ: BIIB) loomed large on the stock market on Wednesday. It published its latest set of ...

Key dosing differences between Eli Lilly’s Kisunla and Biogen’s Leqembi are about to come to a head in the Alzheimer's market ...

Biogen reported better-than-expected first-quarter earnings and revenue on Wednesday, and trimmed its full-year earnings outlook, citing charges related to business development activity.

With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights ...

Full-year 2026 revenue guidance of $840 million to $870 million remains unchanged as management awaits a full quarter of post ...

Biogen (BIIB) stock is in focus as the company inks a deal worth up to $850M with TJ Bio to buy Greater China rights to ...

With this transaction, Biogen now owns exclusive worldwide development and commercialization rights to felzartamab, consolidating global rights under one owner -- Advancing felzartamab -- a ...

Biogen Inc. (NASDAQ: BIIB) stock climbed Monday as the company and TJ Biopharma announced that the companies have entered into a definitive agreement under which Biogen has agreed to acquire TJ Bio’s ...

Biogen lowered its earnings guidance and projected weaker revenue for 2026, tempering the impact of a first-quarter rise in ...

Stoke Therapeutics, Inc.: late-stage zorevunersen for SCN1A Dravet Syndrome with durable 3-year data, Phase 3 EMPEROR and ...

CAMBRIDGE, Mass. and HANGZHOU, China, April 20, 2026 /PRNewswire/ -- Biogen Inc. (Nasdaq: BIIB) and TJ Biopharma ("TJ Bio") today announced that the companies have entered into a definitive agreement ...

Irish parliamentary exchanges over rare disease treatment expose delays in the approval process that leave the country ranked ...